| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2015: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
The nucleic acid innovative drug development is expected as a new therapeutic method for the refractory disease.We make the original nucleic acid as Japan original and aim at the innovative drug development to respiratory disease with the administration of the trans-airway.As a result of designing a nucleic acid using a mouse disease model, and having tested it, control of the disease clinical condition was found to be possible by a trans-airway nucleic acid medication.These results suggest that intra-tracheal instillation of RNAi agents may be useful for the therapy of pulmonary diseases.
|
